Blog
RSS FeedPosted by Michael Wonder on 15 May 2019
Homology Medicines announces FDA fast track designation for HMI-102 gene therapy development candidate for adults with PKU
14 May 2019 - Company provides details of pheNIX, the first gene therapy trial for PKU, and remains on track to ...
Posted by Michael Wonder on 15 May 2019
FDA approves Bavencio (avelumab) plus axitinib combination for patients with advanced renal cell carcinoma
14 May 2019 - Phase III study showed combination significantly lowered risk of disease progression or death by 31% and extended ...
Posted by Michael Wonder on 14 May 2019
A new study sparks a war of words over the drug industry’s commitment to research
14 May 2019 - The pharmaceutical industry spends about $1 in $5 of its revenues on research and development. ...
Posted by Michael Wonder on 14 May 2019
FDA approves Eylea (aflibercept) injection for diabetic retinopathy
13 May 2019 - Eylea improves diabetic retinopathy and prevents worsening disease that can lead to blindness. ...
Posted by Michael Wonder on 14 May 2019
FDA approves broadened indication for Xeomin (incobotulinumtoxinA) as first-line treatment for blepharospasm (involuntary blinking) in adult patients
13 May 2019 - Merz Americas announced today that the U.S. FDA has approved the supplemental biologics license application for Xeomin ...
Posted by Michael Wonder on 14 May 2019
Cellectar receives FDA fast track designation for CLR 131 in relapsed or refractory multiple myeloma
13 May 2019 - Designation could accelerate CLR 131 development and underscores the need for new treatments. ...
Posted by Michael Wonder on 14 May 2019
Celgene Corporation announces Pomalyst granted breakthrough therapy designation from FDA for HIV positive and negative Kaposi sarcoma
13 May 2019 - Celgene plans to submit sNDA by end of 2019. ...
Posted by Michael Wonder on 13 May 2019
Novartis pitches discounts on pricey gene therapy for deadly muscle disorder
11 May 2019 - Novartis is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal ...
Posted by Michael Wonder on 13 May 2019
Considerations in demonstrating interchangeability with a reference product guidance for industry
9 May 2019 - This guidance is intended to assist sponsors in demonstrating that a proposed therapeutic protein product is interchangeable ...
Posted by Michael Wonder on 13 May 2019
Safety, efficacy, and quality remain top priorities as we continue our work to expand access to cost-saving generic drugs for the American public
13 May 2019 - Millions of Americans have difficulty paying for their prescription medications. ...
Posted by Michael Wonder on 13 May 2019
Two words to help Ned Sharpless revolutionise clinical trials: data standards
13 May 2019 - In the classic 1967 film “The Graduate,” young Benjamin Braddock was given one word of advice ...
Posted by Michael Wonder on 13 May 2019
Grandstanding, not real change: why drug prices in TV ads will be confusing and irrelevant
13 May 2019 - In a fit of hubris, President Trump believes he is making drug makers “come clean” by ...
Posted by Michael Wonder on 13 May 2019
Lilly's Cyramza (ramucirumab) becomes first FDA approved biomarker-driven therapy in patients with hepatocellular carcinoma
13 May 2019 - This new indication - the fifth FDA approval for Cyramza in an advanced or metastatic cancer - ...
Posted by Michael Wonder on 13 May 2019
Intellipharmaceutics announces FDA approval for generic Pristiq
10 May 2019 - Intellipharmaceutics announced today that it has received approval from the U.S. FDA for the Company's abbreviated new ...
Posted by Michael Wonder on 12 May 2019
Teva and other generic drug makers inflated prices up to 1,000%, State prosecutors say
11 May 2019 - According to a new lawsuit, generic medications including oral antibiotics, blood thinners, cancer drugs, contraceptives and HIV ...